Lars Ueberdiek1
Ulrich Jehn
Stefan Reuter- 1Department of Medicine D, Transplant Nephrology, University Clinics Muenster, Muenster, Germany
- 2Department of Cardiology I—Coronary and Peripheral Vascular Disease, Heart Failure, University Clinics Muenster, Muenster, Germany
A Corrigendum on
Novel Therapeutic Strategies for Dyslipidemia: First Report of Inclisiran Therapy in a Kidney Transplanted Patient
by Ueberdiek L, Jehn U, Pavenstädt H, Gebauer K and Reuter S (2023). Transpl. Int. 36:11104. doi: 10.3389/ti.2023.11104
In the original article, there was an error. The injection type listed for the administration of Inclisiran was incorrect.
A correction has been made to paragraph 6:
“Inclisiran (284 mg i.m.) was administered at 0 and 3 months and then every 6 months while continuing atorvastatin and ezetimib.”
Has been updated to:
“Inclisiran (284 mg s.c.) was administered at 0 and 3 months and then every 6 months while continuing atorvastatin and ezetimibe.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: kidney transplantation, renal transplantation, dyslipidemia, inclisiran, LDL
Citation: Ueberdiek L, Jehn U, Pavenstädt H, Gebauer K and Reuter S (2023) Corrigendum: Novel Therapeutic Strategies for Dyslipidemia: First Report of Inclisiran Therapy in a Kidney Transplanted Patient. Transpl Int 36:11313. doi: 10.3389/ti.2023.11313
Received: 27 February 2023; Accepted: 14 March 2023;
Published: 23 March 2023.
Copyright © 2023 Ueberdiek, Jehn, Pavenstädt, Gebauer and Reuter. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Stefan Reuter, c3RlZmFuLnJldXRlckB1a211ZW5zdGVyLmRl